Bloom Science to Present at 24th Annual Biotech in Europe Forum
SAN DIEGO, Calif., September 24, 2024 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that its Chief Executive Officer, Christopher Reyes, Ph.D., will be presenting at the 24th Annual Biotech in Europe Forum being held September 25-26, 2024 in Basel Switzerland.
Details are as follows:
- 24rd Annual Biotech in Europe Forum
Details: Dr. Reyes will deliver a corporate presentation and participate in 1-on-1 meetings
Conference dates: September 25-26, 2024
Presentation Timing: 14:05 CEST on September 25, 2024
About Bloom Science, Inc.
Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in Obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.